The COVID-19 mRNA “Vaccines” cause Cancer; here’s the evidence…

The homologous recombination DNA repair pathway is one of the mechanisms that the body uses to stop your cells turning cancerous in response to environmental stress.

One of the most important components of this pathway is Tumor protein P53 (p53), the “guardian of the genome”. It protects our cells from cellular damage. Under cellular stress, p53 jumps into action, regulating gene expression to control DNA repair, cell division and cell death. It is the most commonly mutated gene in cancer.

In October 2021, two revered scientists, called Jiang and Mei, had a paper published, after peer review, in MDPI, showing that the SARS-Cov-2 spike protein obliterated the DNA repair mechanism in lymphocytes.

The viral spike protein was so toxic to this pathway that it knocked 90% of it out. If the whole spike protein got into the nucleus (in the ovaries), and enough of it was produced and hung around long enough before the body was able to get rid of it all, it would cause cancer. Fortunately, in the case of naturally infection, this is unlikely to occur.

Unfortunately, the experimental mRNA toxshot induces spike protein to be produced (the full length spike exactly matching – amino acid for amino acid – the full length of the viral spike protein¹) in and around the cell nucleus² and is produced for at least 60 days and almost certainly longer³.

“Fact checkers” said the viral spike protein doesn’t get in the nucleus despite the expert scientists showing that it absolutely does.

Keep reading

First Patient Dosed With Experimental Cancer-Killing Virus in New Trial

Scientists dosed the first patient this week in a small clinical trial of an experimental cancer treatment—one that relies on a novel kind of ally. The treatment uses a virus engineered to selectively kill cancer cells, while also amplifying the body’s immune response to the cancer. The hope is that this therapy can help those with advanced solid tumor cancers, in combination with other existing drugs.

The CF33-hNIS virus, also called Vaxinia, was originally created by researchers at the City of Hope National Medical Center in California. It’s now being jointly developed with the company Imugene Limited.

Vaxinia is billed as an oncolytic virus, meaning it prefers to target and infect tumor cells. Scientists have been hopeful about using these kinds of viruses to directly kill off cancer cells for more than a century, but with limited success so far. In recent years, some teams have decided to explore a slightly different plan of attack. This genetically modified virus not only infects and harms cancer cells, but also forces these cells to become more recognizable to the immune system.

This strategy, the researchers hope, will then allow other treatments that also boost our immune response to cancer cells to be more effective, particularly against hard-to-target solid tumors. These treatments are collectively known as immunotherapy. In early animal and lab experiments, the virus has been shown to reduce the size of colon, lung, breast, ovarian, and pancreatic cancer tumors.

Keep reading

Nearly 100 people at this NJ school got brain tumors — a survivor demands answers

A cancer survivor is vowing to untangle the twisted mystery of why almost 100 people associated with a New Jersey high school have developed “extremely” rare malignant brain tumors.

Al Lupiano is among the 94 former staff and students from Colonia High School in the Woodbridge Township School District who have been stricken by the devastating diagnoses in recent years.

“I will not rest until I have answers,” Lupiano, 50, declared in an interview with NJ.com and the Star-Ledger on Thursday. “I will uncover the truth.”

Among the others diagnosed with brain cancer was Lupiano’s younger sister, who passed away from the disease in February at the age of 44.

The devoted brother promised his sister on her deathbed that he would get to the bottom of what was causing the apparent cancer cluster at Colonia High. On Tuesday — after a public push by Lupiano — local officials approved an emergency probe of the school.

Keep reading

Researchers Discover Cannabis-Mushroom Combination that ‘Kills Over 90% of Colon Cancer Cells’

For years, when it comes to cannabis research, Israeli scientists have been pioneers. Thanks to the tyrannical schedule one rating in the United States, Israel is years ahead of American research, and the latest information out of Herzliya, Israel, is proof.

Though breast cancer is more diagnosed in the United States, colorectal cancer kills far more people, coming in as the second most deadly cancer in the world, just under lung cancer. For the last several years, scientists with Cannabotech, a biomedical company developing oncological products using cannabis, have been developing an “Integrative-Colon” product they say kills over 90% of colon cancer cells. 

According to Cannabotech, the have concluded a study using not only cannabis, but a unique combination of cannabinoids and mushroom extracts, which they tested on various colon cancer subtypes, representing different molecular changes common in these colon cancer subtypes. Their results of the cell model study were astounding, showing that its “Integrative-Colon” products killed over 90% of colon cancer cells — and they attribute this to to the mushroom and cannabis combination.

Results showed that Cannabotech’s Integrative-Colon products composition is significantly more effective than each cannabinoid individually, and there is a strong synergy between the active ingredients. These results reinforce Cannabotech’s claim that to achieve effective treatment in the oncology field, it is necessary to build a defined, accurate and science-based formula, which cannot be obtained in any cannabis strain that exists in nature.

Given the fact that the survival rate for colorectal cancer is just 65%, the idea that an easily grown plant and fungus could be used to save hundreds of thousands of lives, is inspiring to say the least.

Keep reading

Ivermectin found to suppresses tumour development

Researchers in Japan and the United States have found that ivermectin, a drug used to kill parasites, suppresses tumour development in epithelial ovarian cancer.

Ivermectin exerts an anti-tumour effect on epithelial ovarian cancer (EOC) cells by interacting with the new gene target KPNB1. Because ivermectin is already approved to treat parasitic infections in patients, experiments for its effectiveness in an anti-cancer regimen is expected to significantly lower costs compared to untested drug compounds.

“EOC is a challenging disease to treat because of its heterogeneity. The mortality rate has stayed steady for decades. We need new drugs and also new drug targets,” said Osaka University Gynecologist Michiko Kodama.

Keep reading